AIForbes Innovation1 day ago
The New Billionaire Bet Isn't AI, It's Longevity Biotech
1 min read
Longevity biotech companies raised $3.74 billion across 49 deals in Q1 2026, up 56% year-over-year. Silicon Valley billionaires are shifting focus from AI to rewriting biology. Investors back therapies with clear paths to clinical validation. NewLimit, co-founded by Brian Armstrong, uses AI to accelerate discovery more than twice as fast as human intuition.
Level
Hype check
Tap to vote and see what everyone thinks.
